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To the Editor: The cover of the March 1, 2007 of KI was neat,
especially because it was published in the month of World
Kidney Day. Unfortunately, however, the Japanese word
translates to ‘World Liver Day’ instead of ‘World Kidney Day’.
You can easily tell the difference by comparing the Chinese
Word, which is correct, to the Japanese Word, which is wrong.
M Nangaku1
1Division of Nephrology and Endocrinology, University of Tokyo School of
Medicine, Bunkyo-ku, Tokyo, Japan
Correspondence: M Nangaku, Division of Nephrology and Endocrinology,
University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-
8655, Japan. E-mail: mnangaku-tky@umin.ac.jp
Response
Kidney International (2007) 71, 952. doi:10.1038/sj.ki.5002278
I apologize to Dr Nangaku1 and our Japanese readers for this
gaffe. Our multi-lingual covers have been very popular, and
I had tried to make sure that the translations on them are
correct. I often do so by asking foreign trainees at Columbia
University to check the calligraphy, many of which are
actually supplied by them. As Dr Nangaku correctly points
out, we should have checked the Chinese spelling to confirm
the veracity of the Japanese spelling, but this implies that the
person checking the spelling actually knew the connection
between Japanese and Chinese scripts. Alas, the cause is
much simpler; it was simply total ignorance. We hope that
there will be no repetition of such an error.
1. Nangaku M. Hepato-renal confusion. Kidney Int 2007; 71: 952.
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To the Editor: The October and November 2006 issues of
Kidney International arrived with ‘false’ covers announcing
the entry of Roche into the anemia treatment market. The
‘Kidney International’ name was featured prominently above
the Roche advertisement. Consequently, the covers closely
resembled the true journal cover. Important work by
contributing authors that appeared on the true covers of
each issue was hidden behind these advertisements.
Like all print media, medical journals rely on revenue
from advertisements to cover costs. Nonetheless, a boundary
should exist between medical professionals and the pharma-
ceutical industry. We believe that in allowing false covers to
appear on the October and November editions, Kidney
International crossed that boundary.
Central to the ethics policy of journalism, as applied to
advertisers, is the understanding that news and advertising
are separate, and that advertising must not resemble news
content.1 For example, the television news industry is
currently being investigated by The Federal Communications
Commission for including video news releases or VNRs into
news stories. VNRs are commercials disguised as news. Less
prominent journals use false covers and sometimes national
newspapers run stories that appear to be news articles.
However, a disclaimer will usually be prominently displayed.
The Kidney International false covers contained the phrase
‘see our AD inside,’ but nowhere on the covers was a
disclaimer stating that the covers were not an endorsement of
the product by Kidney International and that the covers were
an advertisement. While most readers will probably realize
that the false covers are advertisements, for all of the reasons
outlined above, these advertisements may create the erro-
neous impression that Kidney International is endorsing the
advertised product.
Other nephrology journals probably face similar decisions
trying to balance the need to increase revenue against the
need to set acceptable limits on honest advertisement. The
November issue of the American Journal of Kidney Diseases
arrived wrapped in a five-inch wide band advertising an
Amgen product. A similar band on the October issue
l e t t e r t o t h e e d i t o r http://www.kidney-international.org
& 2007 International Society of Nephrology
952 Kidney International (2007) 71, 952–954
declared that, ‘The evidence is here,’ in reference to a Wyeth
product. These bands convey the impression of a connection
between scientific evidence for the products, the pharma-
ceutical company, and the independent academic journal.
The November editions of the Journal of the American
Society of Nephrology, American Journal of Kidney Diseases,
and Kidney International contained 30, 19, and 13 advertise-
ments, respectively. Of these three journals, the November
issue of Kidney International actually had the lowest number
of large page advertisements. However, unlike these other
journals, advertisements in Kidney International were not
limited to the pages preceding and following the contents of
the journal but were interspersed. These observations raise
the question of whether journals face a trade-off between
running a larger number of appropriate advertisements or a
lesser number of (presumably more lucrative) inappropriate
advertisements in order to cover costs.
To avoid risking the loss of respect of its readers, we urge
Kidney International to eliminate practices that blur the
boundary between academic pursuits and advertising. If we
are incapable of self-regulation, it will only be a matter of
time before the government steps in to control advertising
practices in medical journals.
1. The New York Times Company Journalism Ethics Policy
http://www.nytco.com/company-journalism-ethics.html.
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Osteodystrophy and dialysis
survival
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To the Editor: In the article by Kalantar-Zadeh 1 we noticed
with interest that the survival benefit granted by paricalcitol
paradoxically decreased with higher doses. Since the latter
doses are more likely to be hyperphosphatemic and
hypercalcemic, this suggests that these deleterious side effects
counterbalance the beneficial effects of paricalcitol related to
partial correction of the usual vitamin D depletion of the
American Dialysis population. Indeed vitamin D deficiency
has been epidemiologically related to a higher risk of diabetes
and cardiovascular risk by activation of inflammation and
this can simply be suppressed by plain vitamin D adminis-
tration.2 This simple measure can furthermore quite
efficiently suppresses parathyroid hormone (PTH) and allow
to limit the dose of the more potent (inappropriately called
‘active’) vitamin D derivatives, while decreasing the risk of
calcification. This is strongly suggested by the comparison of
2 cohorts of young adults with childhood onset of end-stage
renal disease (ESRD):3,4 the Berlin cohort 4 had received
cholecalciferol and a 35-fold lower cumulative dose of ‘active’
vitamin D than that of Heidelberg and its coronary
calcification prevalence was 10% instead of 92%, while their
PTH suppression and demographic characteristics (with the
exception of 2 years less on dialysis and 2 years more on
transplantation) were comparable.
These observations should lead to systematic correction of
vitamin D deficiency, even in dialysis patients, even though
NKF-K/DOQI does recommend it only in chronic kidney
disease (CKD) patients stage 3–4, but paradoxically not in
ESRD patients in whom vitamin D deficiency is more severe.
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patients. Kidney Int 2006; 70: 771–780.
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3. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid
arteriopathy in young adults with childhood-onset chronic renal failure.
Circulation 2002; 106: 100–105.
4. Briese S, Wiesner S, Will JC et al. Arterial and cardiac disease in young
adults with childhood-onset end-stage renal disease-impact of calcium
and vitamin D therapy. Nephrol Dial Transplant 2006; 21: 1906–1914.
JF Bonne1, S Mailliez1, M Assem Al Rifai1, I Shahapuni1,
J Mansour1 and A Fournier1
1Department of Nephrology, CHU, AMIENS, France
E-mail: albert@chu-amiens.fr
Response to ‘Osteodystrophy and
dialysis survival’
Kidney International (2007) 71, 953–954. doi:10.1038/sj.ki.5002219
We appreciate the comments by Bonne et al.1 The apparent
mitigation of the survival advantage of higher doses of
vitamin D was only observed with paricalcitol doses above
15 mcg/week.2 Patients in the latter group had an average
serum intact PTH concentration of 555 pg/ml, compared
with 268 pg/ml in all other patients.2 Hence, the weaker
survival advantage in the high-dose paricalcitol group is
not unlikely due to a high baseline PTH at the start of the
cohort. Both we2 and others3 have shown that severe
hyperparathyroidism is associated with increased death
risk. Such excessive serum PTH concentrations usually
lead to secondary administration of higher doses of
vitamin D by nephrologists. The resultant ‘selection bias
by indication’ may appear in the form of a spurious
association between vitamin D dose and outcome. Never-
theless, it should be emphasized that in our study even
patients who had received the highest paricalcitol dose
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